DAX-0,22 % EUR/USD+0,01 % Gold+0,07 % Öl (Brent)-2,32 %

AveXis Announces Innovative Zolgensma Gene Therapy Access Programs for US Payers and Families

Nachrichtenquelle: GlobeNewswire
24.05.2019, 18:42  |  719   |   |   

Novartis International AG / AveXis Announces Innovative Zolgensma Gene Therapy Access Programs for US Payers and Families . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

  • One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA
     
Novartis mit festem Hebel folgen [Werbung]
Ich erwarte, dass der Novartis steigt...
Ich erwarte, dass der Novartis fällt...

Verantwortlich für diese Werbung ist die Deutsche Bank AG. Die Wertpapierprospekte und Basisinformationsblätter zu diesen Produkten erhalten Sie über www.xmarkets.db.com. Disclaimer

  • Annualized cost of Zolgensma is USD 425,000 per year for 5 years: 50% less than multiple established value-based pricing benchmarks including the 10-year current cost of chronic SMA therapy[1]
     
  • AveXis is working closely with payers to create 5-year outcomes-based agreements and novel pay-over-time options; Time is Neurons program to support rapid SMA treatment post-diagnosis
     
  • Comprehensive OneGene ProgramTM provides dedicated, personalized support for Zolgensma patients
  • Basel, May 24, 2019 - AveXis, a Novartis company, today announced innovative access programs for Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. AveXis is working closely with payers to offer pay-over-time options up to 5 years and outcomes-based agreements up to 5 years, as well as providing a patient program to support affordability and access.

    "Zolgensma is a historic advance for the treatment of SMA and a landmark one-time gene therapy. Our goal is to ensure broad patient access to this transformational medicine and to share value with the healthcare system," said Vas Narasimhan, CEO of Novartis. "We have used value based pricing frameworks to price Zolgensma at around 50% less than multiple established benchmarks including the 10-year current cost of chronic SMA therapy.  In addition, the price of Zolgensma is expected to be within the range of traditional cost-effectiveness thresholds used by ICER when updated for its full labeled indications. We believe by taking this responsible approach, we will help patients benefit from this transformative medical innovation and generate significant cost savings for the system over time."

    Diesen Artikel teilen
    Seite 1 von 11

    Diskussion: In 10 Schritten schweizerische Quellensteuer am Beispiel von Novartis zurückfordern
    Wertpapier

    Mehr zum Thema
    Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
    EuroUSDTwitterJapanIBM Watson


    0 Kommentare

    Schreibe Deinen Kommentar

    Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

     

    Disclaimer

    Aus der Community
    LUS Wikifolio-Index BITCOIN performance Index Zertifikat Open-End (LASW)
    Chart: arniarni
    LUS Wikifolio-Index BITCOIN, ETHEREUM & GOLD Index Zertifikat Open-End (LASW)
    Chart: arniarni
    LUS Wikifolio-Index Sehr bekannte Kryptowaehrung Index Zertifikat Open-End (LASW)
    Chart: arniarni